Table 5 Late adverse effects at 3 years after tandem HDCT/auto-SCT

 Hypothyroidism, n (%)

12 (37.5)

11 (40.7)

0.799

 Growth hormone deficiency, n (%)

9 (28.1)

1 (3.7)

0.016

 Glucocorticoid deficiency, n (%)

1 (3.1)

0 (0.0)

0.542

 Sex hormone deficiency, n (%)

1/2^a (50.0)

1/3^a (33.3)

0.700

Height, Z-score, median (range)

−1.46 (−5.66–0.93)

−0.65 (−2.78–1.40)

0.004

Weight, Z-score, median (range)

−0.84 (−2.91–0.75)

−0.32 (−2.15–2.08)

0.014

BMI, Z-score, median (range)

−0.38 (−2.58–1.62)

−0.42 (−1.86–2.68)

0.166

Hearing loss, n (%)

24 (75.0)

16 (59.3)

0.197

Cataract, n (%)

9 (28.1)

0 (0)

0.002

Chronic lung disease, n (%)

2 (6.3)

0 (0.0)

0.673

 Glomerulopathy, n (%)

18 (56.3)

4 (14.8)

0.001

 Tubulopathy, n (%)

20 (62.5)

17 (63.0)

0.971

Cardiac dysfunction, n (%)

0 (0.0)

0 (0.0)

1.000

Presence of grade 3 dysfunction, n (%)

4 (12.5)

2 (7.4)

0.678

Number of dysfunctions/patient, median (range)

3 (0–7)

2 (0–4)

0.003